Table 1.
Patients’ characteristics.
| Rheumatoid Arthritis | Multiple Sclerosis | Systemic Lupus Erythematosus | |
|---|---|---|---|
| Patients (n) | 47 | 10 | 10 |
| Age (years median, min - max) | 53 (18-71) | 46 (39-70) | 35.5 (30-60) |
| Female (n, %) | 33 (70) | 7 (70) | 9 (90) |
| IgM RF positive (n, %) | 24 (51) | n/a | 0 |
|
Anti-CCP2 positive
(n, %) |
31 (66) | n/a | n/a |
|
Treated with IFX
(n, %) |
7 (15) | 0 | 0 |
|
Treated with RTX
(n, %) |
0 | 0 | 10 (100) |
| Treated with IFN beta-1a (n, %) | 0 | 10 (100) | 0 |
| ADA positive (n, %) | n/a | 3 (30) | 5 (50) |
| Time period of sampling | 1998 - 2006* | 2003 - March 2019 | 2003 - 2018 |
n, number; RF, rheumatoid factor; anti-CCP, anti-cyclic citrullinated peptide; IFX, infliximab; RTX, rituximab; IFN interferon; ADA, anti-drug antibodies; n/a, not applicable; RA, rheumatoid arthritis.
*Time period of sampling for RA patients treated with IFX: 2018 - March 2019.